Quick Answer
Gain Therapeutics, Inc. reported Stockholders Equity of $18.56 million for fiscal year 2025.
Gain Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $18.56M | +152.9% |
| 2024 | $7.34M | -41.6% |
| 2023 | $12.58M | -33.4% |
| 2022 | $18.88M | -45.8% |
| 2021 | $34.82M | +461.4% |
| 2020 | $6.20M | +1478.7% |
| 2019 | -$449.9K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.91M | -33.7% | +59.9% |
| June 30, 2025 | $3.70M | -68.6% | -36.1% |
| March 31, 2025 | $5.78M | -33.1% | -21.3% |
| December 31, 2024 | $7.34M | -41.6% | -17.6% |
| September 30, 2024 | $8.91M | +21.5% | -24.4% |
| June 30, 2024 | $11.78M | +6.2% | +36.4% |
| March 31, 2024 | $8.64M | -42.9% | -31.3% |
| December 31, 2023 | $12.58M | -33.4% | +71.6% |
- Gain Therapeutics, Inc. showed an increase of +152.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Gain Therapeutics, Inc.’s stockholders equity has grown by 4226.8% (from -$449.9 thousand to $18.56 million).
- The most recent figure is from Gain Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: